Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 19, 2025, 7am CET.  Ad hoc announcement pursuant to Art. 53 LR Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination with first-line TB  [ … ]

BioVersys AG / Key word(s): Annual Results BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS 14.03.2025 / 07:00 CET/CEST Basel, Switzerland. March 14, 2025, 7am CET BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of  [ … ]

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 10, 2025, 7am CET.  Ad hoc announcement pursuant to Art. 53 LR Partial exercise of over-allotment option following end of stablization period in context of the company’s initial public offering (IPO) An additional 47,862 new shares to be issued by BioVersys BioVersys raised tot [ … ]

BioVersys AG / Key word(s): Miscellaneous BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE 11.02.2025 / 07:00 CET/CEST Basel, Switzerland. February 11, 2025, 7am CET   BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead c [ … ]

BioVersys AG / Key word(s): IPO BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST __________ THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMU [ … ]